Meeting
2022 ASCO Annual Meeting
Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in solid tumors: Data-mining of 1,382 electronic patient records.
Authors
Mathilde Beaufils
Institut Paoli-Calmettes, Marseille, France
Mathilde Beaufils , Vincent Amodru , Manuel Tejeda , Brice Chanez , Anne Sophie Chretien , Gwenaelle Gravis , Anne Madroszyk , Anthony Goncalves , Aaron E. Lisberg , Daniel Olive , Louis Tassy , Frédéric Castinetti , Philippe Rochigneux
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2659)
DOI
10.1200/JCO.2022.40.16_suppl.2659
Abstract #
2659
Poster Bd #
313
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis.
First Author: Vaia Florou
Poster
2020 ASCO Virtual Scientific Program
Impact of performance status on response and survival among patients receiving checkpoint inhibitors for advanced solid tumors.
First Author: Mridula Krishnan
Poster
2024 ASCO Genitourinary Cancers Symposium
PEMBROBLAD: Real world effectiveness and safety of immune checkpoint inhibitors in patients with advanced urothelial carcinoma with histological variants.
First Author: Karim Amrane Sr.
Poster
2023 ASCO Annual Meeting
Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study.
First Author: Tämer El Saadany